Skip to content


Adiposs is developing ImageBAT™, a first-in-class CT contrast agent for brown fat.

ImageBAT™ is a non-invasive, pain-free product, compatible with all CT scanners available in hospitals worldwide.

It is the first diagnostic imaging product to identify patients with increased risks of cancer progression, higher risk of treatment failure and shorter survival.

Our news



October 2, 2023

Adiposs welcomes two new board directors




September 14, 2023

Adiposs completes ImageBATTM phase I clinical trial


September 8, 2023

Adiposs receives TOP 100 Swiss Startups Award 2023


May 23, 2023

Adiposs has won the pitching battle at the Swiss startup days 2023!


Andrej BABIC PhD

Chief Executive Officer


Chief Technology Officer


Chief Development Officer

Hervé Porchet MD

Chief Medical Officer

Our partners


c/o Fongit
Route de la Galaise 34
1228 Plan-les-Ouates

Subscribe to our newsletter

Andrej BABIC

Chief Executive Officer

Andrej is the Chief Executive Officer and co-founder of Adiposs. He holds a master’s degree in pharmaceutical sciences and a PhD in pharmaceutical chemistry. Andrej is the co-inventor of ImageBAT. He was a senior lecturer in pharmaceutics at the University of Geneva, where he developed molecules for diagnosis of diabetes, obesity and cancer. Andrej has co-authored more than 30 scientific papers and holds several patents in the fields of medical imaging, photodynamic therapy and nanotechnology. He has worked in the field of diagnostic medical imaging for over 10 years leading multidisciplinary teams and projects in academia and start-up companies.


Chief Technical Officer

Nathalie is the Chief Technical Officer of Adiposs. She holds a master’s degree in pharmacy and a PhD in pharmaceutical technology from the University of Geneva. She is responsible for preclinical development of ImageBAT and GMP production. Nathalie has 10 years of experience in the development of advanced nanotechnology pharmaceutical systems and medical imaging agents in academia and start-up companies.  She also has experience in designing clinical trials and is coordinating activities of the clinical pipeline of Adiposs.


Chief Development Officer


Duc brings to Adiposs over twenty years of experience in drug discovery and drug development from big pharma companies (Sanofi-Aventis, Pfizer, Lundbeck) and biotech start-ups (Preglem, Arisgen, EspeRare, Prexton Therapeutics). Duc’s experience extends across multiple therapeutic areas including cardiovascular, anti-infective, urology, epigenetics, CNS, rare disease and reproductive medicine. He has successfully delivered a number of projects into clinical development, up to registration. At Adiposs, Duc is responsible for providing IND-enabling Preclinical, Early Clinical, and Chemistry, Manufacturing and Control (CMC) leadership to support regulatory submissions.


Chief Medical Officer

Hervé is the Chief Medical Officer of Adiposs. He has extensive experience in clinical & preclinical drug development in various therapeutic areas, including oncology, CNS, hepatology, infections, and endocrinology. He worked as a clinical pharmacologist at the interface of preclinical and clinical development & promoting translational medicine to achieve a rational and efficient drug development. Hervé is a strong supporter of the use of biomarkers in conjunction with PK-PD modelling & population PK.